COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA.

Nicola A Hanania,Scott H Bunner,Lindsay G S Bengtson,Afisi S Ismaila,Michael Bogart

International journal of chronic obstructive pulmonary disease（2023）

引用 0|浏览7

暂无评分

摘要

In a real-world setting, patients on MITT who subsequently initiated FF/UMEC/VI in a single device had significant reductions in the rate of COPD exacerbations (moderate or severe). Switching to FF/UMEC/VI also resulted in improvements in some HCRU and cost outcomes. These data support the use of FF/UMEC/VI among patients at high risk of exacerbation to reduce future risk and improve outcomes.

查看译文

关键词

FF/UMEC/VI,chronic obstructive pulmonary disease,exacerbations,healthcare utilization,multiple-inhaler triple therapy,single-inhaler triple therapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要